First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects

We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects aged 18–40 years were enrolled in this two-part study: Part 1, a single asce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meng-na, Kuang, Yun, Gong, Li-ying, Hua, Ye, Pei, Qi, Guo, Cheng-xian, Cao, Yu, Huang, Jie, Yang, Guo-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575490/
https://www.ncbi.nlm.nih.gov/pubmed/32535812
http://dx.doi.org/10.1007/s10637-020-00959-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575490/
https://www.ncbi.nlm.nih.gov/pubmed/32535812
http://dx.doi.org/10.1007/s10637-020-00959-6

Ejemplares similares